{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:43:11Z","timestamp":1768927391350,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T00:00:00Z","timestamp":1524700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.oret.2018.04.018","type":"journal-article","created":{"date-parts":[[2018,6,10]],"date-time":"2018-06-10T23:20:32Z","timestamp":1528672832000},"page":"1087-1096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7811-7132","authenticated-orcid":false,"given":"Marco A.","family":"Zarbin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Francom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Grzeschik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Tuomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zdenka","family":"Haskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Macfadden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Margaron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-1448","authenticated-orcid":false,"given":"Howard","family":"Snow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Cruess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2299-5251","authenticated-orcid":false,"given":"Giovanni","family":"Staurenghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Dunger-Baldauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2018.04.018_bib1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2018.04.018_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.018_bib3","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.018_bib4","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2018.04.018_bib5","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2018.04.018_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.oret.2018.04.018_bib7","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2018.04.018_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.018_bib9","series-title":"Eylea (aflibercept) injection prescribing information","year":"2015"},{"key":"10.1016\/j.oret.2018.04.018_bib10","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ophtha.2011.09.044","article-title":"Age-related macular degeneration and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis","volume":"119","author":"Fernandez","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.018_bib11","doi-asserted-by":"crossref","first-page":"502","DOI":"10.14423\/SMJ.0000000000000329","article-title":"Age-related macular degeneration and coronary artery disease in a VA population","volume":"108","author":"Thomas","year":"2015","journal-title":"South Med J"},{"key":"10.1016\/j.oret.2018.04.018_bib12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/STROKEAHA.109.571000","article-title":"Neovascular age-related macular degeneration and the risk of stroke: a 5-year population-based follow-up study","volume":"41","author":"Hu","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.oret.2018.04.018_bib13","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1161\/STROKEAHA.112.654632","article-title":"Age-related macular degeneration and long-term risk of stroke subtypes","volume":"43","author":"Ikram","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.oret.2018.04.018_bib14","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1161\/STROKEAHA.111.616359","article-title":"Age-related macular degeneration and the risk of stroke: the Rotterdam study","volume":"42","author":"Wieberdink","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.oret.2018.04.018_bib15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/bjo.2007.131706","article-title":"Age-related macular degeneration and mortality from cardiovascular disease or stroke","volume":"92","author":"Tan","year":"2008","journal-title":"Br\u00a0J Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.018_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajo.2010.04.011","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2","volume":"150","author":"Abraham","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.018_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.018_bib18","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","article-title":"A\u00a0Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration","volume":"116","author":"Boyer","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.018_bib19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.oret.2018.04.018_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1755-3768.2009.01843.x","article-title":"EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration","volume":"88","author":"Tano","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.018_bib21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study","volume":"118","author":"Schmidt-Erfurth","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.018_bib22","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.018_bib23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamaophthalmol.2017.0455","article-title":"Vascular safety of ranibizumab in patients with diabetic macular edema: a pooled analysis of patient-level data from randomized clinical trials","volume":"135","author":"Zarbin","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.018_bib24","series-title":"Lucentis (ranibizumab injection) intravitreal injection prescribing information","year":"2015"},{"key":"10.1016\/j.oret.2018.04.018_bib25","series-title":"Lucentis (ranibizumab) summary of product characteristics","year":"2015"},{"key":"10.1016\/j.oret.2018.04.018_bib26","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1097\/IAE.0b013e31825db6ba","article-title":"Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials","volume":"32","author":"Bressler","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.oret.2018.04.018_bib27","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaophthalmol.2014.2333","article-title":"Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis","volume":"132","author":"Thulliez","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.018_bib28","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.ophtha.2014.05.022","article-title":"Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials","volume":"121","author":"Ueta","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.018_bib29","doi-asserted-by":"crossref","first-page":"e4203","DOI":"10.1136\/bmj.e4203","article-title":"Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study","volume":"345","author":"Campbell","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2018.04.018_bib30","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","article-title":"Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration","volume":"128","author":"Curtis","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.018_bib31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0163278702025001006","article-title":"To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data","volume":"25","author":"Stewart","year":"2002","journal-title":"Eval Health Prof"},{"key":"10.1016\/j.oret.2018.04.018_bib32","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/bjophthalmol-2013-303232","article-title":"Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme","volume":"97","author":"Holz","year":"2013","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653017306796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653017306796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:24:23Z","timestamp":1762853063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653017306796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S2468653017306796"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2018.04.018","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2018.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license (<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}